| 25.51 -0.15 (-0.58%) | 05-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.29 | 1-year : | 36.54 |
| Resists | First : | 26.79 | Second : | 31.29 |
| Pivot price | 25.19  |
|||
| Supports | First : | 24.87 | Second : | 23.69 |
| MAs | MA(5) : | 25.44 |
MA(20) : | 25.31 |
| MA(100) : | 23.28 |
MA(250) : | 19.12 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.5  |
D(3) : | 53.3 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 27 | Low : | 13.47 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XOMA ] has closed below upper band by 38.8%. Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.93 - 26.06 | 26.06 - 26.18 |
| Low: | 25.04 - 25.2 | 25.2 - 25.35 |
| Close: | 25.22 - 25.47 | 25.47 - 25.72 |
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Sat, 18 May 2024
XOMA (NASDAQ:XOMA) Shares Pass Above Two Hundred Day Moving Average of $21.30 - MarketBeat
Wed, 15 May 2024
(XOMA) Investment Analysis - Stock Traders Daily
Tue, 14 May 2024
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect - GlobeNewswire
Mon, 13 May 2024
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities - br.ADVFN.com
Fri, 10 May 2024
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss - Yahoo Finance
Tue, 07 May 2024
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 65.1 (%) |
| Shares Short | 282 (K) |
| Shares Short P.Month | 275 (K) |
| EPS | -4.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.71 |
| Profit Margin | 0 % |
| Operating Margin | -310 % |
| Return on Assets (ttm) | -7.4 % |
| Return on Equity (ttm) | -38.4 % |
| Qtrly Rev. Growth | 23.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.4 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -6.32 |
| PEG Ratio | -0.6 |
| Price to Book value | 3.3 |
| Price to Sales | 62.32 |
| Price to Cash Flow | -16.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|